RecruitingNot ApplicableNCT05858398

Influence of Body Composition on Chemotherapy Outcomes in Localized Breast Cancer

Influence of Body Composition, Total Body Fat and Body Mass Index on the Pharmacokinetics of Docetaxel in Localized Breast Cancer

Sponsor

Centre Henri Becquerel

Enrollment

48 participants

Start Date

Oct 25, 2023

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

The purpose of this study is to determine if pharmacokinetics of docetaxel is modified by the body composition (assessed by the BMI but also by CT-scan) in patients treated by docetaxel as adjuvant treatment of a localized breast cancer

Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria4

Woman older than
Early breast cancer
CT-scan of less than 3 months, including L3 level
Indication of docetaxel at 100 mg/m² as adjuvant CT

Exclusion Criteria6

HER2 amplified or triple negative tumors
Pregnant or breastfeeding women
Patients under guardianship or curatorship
Concomitant administration of another cytotoxic drug or targeted therapy
Psychosocial disorder
Administration of another cytotoxic drug or targeted therapy within 20 days prior to blood collection